LILRB2 and acute myeloid leukemia: Based on sizeable extensive transcriptomics and proteomics databases from malignant and normal tissues in acute myeloid leukemia, suitable pairs such as CD33 + ADGRE2, CLEC12A + CCR1, CD33 + CD70, and LILRB2 + CLEC12A were found to be capable of enhancing CAR-T effect without increasing extra-tumor toxicity [119].